Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416.

Ye C, Sweeny D, Sukbuntherng J, Zhang Q, Tan W, Wong S, Madan A, Ogilvie B, Parkinson A, Antonian L.

Toxicol In Vitro. 2006 Mar;20(2):154-62. Review.

PMID:
16321501
2.

Biotransformation of the anti-angiogenic compound SU5416.

Antonian L, Zhang H, Yang C, Wagner G, Shawver LK, Shet M, Ogilvie B, Madan A, Parkinson A.

Drug Metab Dispos. 2000 Dec;28(12):1505-12.

3.

A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance.

Salzberg M, Pless M, Rochlitz C, Ambrus K, Scigalla P, Herrmann R.

Invest New Drugs. 2006 Jul;24(4):299-304.

PMID:
16237511
4.

Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.

Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A.

Clin Cancer Res. 2002 Sep;8(9):2798-805.

5.

Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.

Katanasaka Y, Ida T, Asai T, Shimizu K, Koizumi F, Maeda N, Baba K, Oku N.

Cancer Lett. 2008 Nov 8;270(2):260-8. doi: 10.1016/j.canlet.2008.05.009. Epub 2008 Jun 13.

PMID:
18555591
6.

Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416.

Sukbuntherng J, Cropp G, Hannah A, Wagner GS, Shawver LK, Antonian L.

J Pharm Pharmacol. 2001 Dec;53(12):1629-36.

PMID:
11804393
7.
8.
9.

Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416.

Loges S, Tinnefeld H, Metzner A, Jücker M, Butzal M, Bruweleit M, Fischer U, Draab E, Schuch G, O'-Farrel AM, Hossfeld DK, Bokemeyer C, Fiedler W.

Leuk Lymphoma. 2006 Dec;47(12):2601-9.

PMID:
17169805
11.

A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers.

Fury MG, Zahalsky A, Wong R, Venkatraman E, Lis E, Hann L, Aliff T, Gerald W, Fleisher M, Pfister DG.

Invest New Drugs. 2007 Apr;25(2):165-72. Epub 2006 Sep 16.

PMID:
16983506
12.

Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia.

Mesters RM, Padró T, Bieker R, Steins M, Kreuter M, Göner M, Kelsey S, Scigalla P, Fiedler W, Büchner T, Berdel WE.

Blood. 2001 Jul 1;98(1):241-3.

13.

Simultaneous determination of SU5416 and its phase I and phase II metabolites in rat and dog plasma by LC/MS/MS.

Zhao Y, Yang CY, Haznedar J, Antonian L.

J Pharm Biomed Anal. 2001 Jul;25(5-6):821-32.

PMID:
11377065
14.

VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.

Ou XM, Li WC, Liu DS, Li YP, Wen FQ, Feng YL, Zhang SF, Huang XY, Wang T, Wang K, Wang X, Chen L.

Int Immunopharmacol. 2009 Jan;9(1):70-9. doi: 10.1016/j.intimp.2008.10.002. Epub 2008 Oct 29.

PMID:
18976720
15.

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.

O'Donnell A, Padhani A, Hayes C, Kakkar AJ, Leach M, Trigo JM, Scurr M, Raynaud F, Phillips S, Aherne W, Hardcastle A, Workman P, Hannah A, Judson I.

Br J Cancer. 2005 Oct 17;93(8):876-83.

16.

VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.

Roscoe WA, Welsh ME, Carter DE, Karlik SJ.

J Neuroimmunol. 2009 Apr 30;209(1-2):6-15. doi: 10.1016/j.jneuroim.2009.01.009. Epub 2009 Feb 23.

PMID:
19233483
17.

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.

Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, Chen D, Gan Y, Kumar G, Meyer J, Neervannan S, Alva G, Talvenheimo J, Montestruque S, Tasker A, Patel V, Radinsky R, Kendall R.

Cancer Res. 2006 Sep 1;66(17):8715-21.

18.

Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits.

Patyna S, Haznedar J, Morris D, Freshwater K, Peng G, Sukbuntherng J, Chmielewski G, Matsumoto D.

Birth Defects Res B Dev Reprod Toxicol. 2009 Jun;86(3):204-13. doi: 10.1002/bdrb.20194.

PMID:
19294680
19.

Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.

Kieran MW, Supko JG, Wallace D, Fruscio R, Poussaint TY, Phillips P, Pollack I, Packer R, Boyett JM, Blaney S, Banerjee A, Geyer R, Friedman H, Goldman S, Kun LE, Macdonald T; Pediatric Brain Tumor Consortium.

Pediatr Blood Cancer. 2009 Feb;52(2):169-76. doi: 10.1002/pbc.21873.

20.

Sunitinib: from rational design to clinical efficacy.

Chow LQ, Eckhardt SG.

J Clin Oncol. 2007 Mar 1;25(7):884-96. Review.

PMID:
17327610
Items per page

Supplemental Content

Write to the Help Desk